

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

April 22, 2004

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 20, 2004

MEDICIS PHARMACEUTICAL CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware	0-18443	52-1574808
(State or Other	(Commission File Number)	(IRS Employer
Jurisdiction of Incorporation)		Identification No.)

8125 North Hayden Road	
Scottsdale, Arizona	85258-2463
(Address of Principal	(Zip Code)
Executive Offices)	

Registrant's telephone number, including area code: (602) 808-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

=====

Item 5. Other Events and Regulation FD Disclosure

On April 20, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had entered into an asset purchase agreement, license agreement and securities purchase agreement with BioMarin Pharmaceutical, Inc.

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

A copy of the Company's press release is attached hereto as Exhibit 99.1.

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated April 20, 2004, issued by Medicis Pharmaceutical Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION
(Registrant)

Date: April 21, 2004

/s/ Mark A. Prygocki, Sr.

Name: Mark A. Prygocki, Sr.
Title: Executive Vice President,
Chief Financial Officer,
Corporate Secretary and
Treasurer

EXHIBIT INDEX

EXHIBIT
NUMBER

DESCRIPTION

99.1

Copy of press release, dated April 20, 2004, issued by
Medicis Pharmaceutical Corporation